ES2478447T3 - Formulaciones del ácido desoxicólico y sus sales - Google Patents

Formulaciones del ácido desoxicólico y sus sales Download PDF

Info

Publication number
ES2478447T3
ES2478447T3 ES11178538.2T ES11178538T ES2478447T3 ES 2478447 T3 ES2478447 T3 ES 2478447T3 ES 11178538 T ES11178538 T ES 11178538T ES 2478447 T3 ES2478447 T3 ES 2478447T3
Authority
ES
Spain
Prior art keywords
deoxycholic acid
formulations
salts
salt
maintained
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11178538.2T
Other languages
English (en)
Inventor
Robert Emil Hodge
Jeffrey Douglas Webster
Robert M. Moriarty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kythera Biopharmaceuticals LLC
Original Assignee
Kythera Biopharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kythera Biopharmaceuticals LLC filed Critical Kythera Biopharmaceuticals LLC
Application granted granted Critical
Publication of ES2478447T3 publication Critical patent/ES2478447T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica acuosa estable a la precipitación que consiste esencialmente en de 0,4% p/v a 1% p/v de una sal del ácido desoxicólico y un excipiente farmacéuticamente aceptable, y en donde dicha composición se mantiene a un pH de 8,2 a 8,5.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12

Claims (1)

  1. imagen1
    imagen2
ES11178538.2T 2011-08-23 2011-08-23 Formulaciones del ácido desoxicólico y sus sales Active ES2478447T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11178538.2A EP2561876B1 (en) 2011-08-23 2011-08-23 Formulations of Deoxycholic Acid and Salts Thereof

Publications (1)

Publication Number Publication Date
ES2478447T3 true ES2478447T3 (es) 2014-07-22

Family

ID=44651163

Family Applications (3)

Application Number Title Priority Date Filing Date
ES11178538.2T Active ES2478447T3 (es) 2011-08-23 2011-08-23 Formulaciones del ácido desoxicólico y sus sales
ES17188946T Active ES2738500T3 (es) 2011-08-23 2011-08-23 Formulaciones de ácido desoxicólico y sales del mismo
ES14155614.2T Active ES2655465T3 (es) 2011-08-23 2011-08-23 Formulaciones del ácido desoxicólico y sus sales

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES17188946T Active ES2738500T3 (es) 2011-08-23 2011-08-23 Formulaciones de ácido desoxicólico y sales del mismo
ES14155614.2T Active ES2655465T3 (es) 2011-08-23 2011-08-23 Formulaciones del ácido desoxicólico y sus sales

Country Status (11)

Country Link
EP (4) EP3305298B1 (es)
CY (1) CY1115372T1 (es)
DK (2) DK2561876T3 (es)
ES (3) ES2478447T3 (es)
HR (1) HRP20140676T1 (es)
HU (1) HUE046047T2 (es)
PL (2) PL3305298T3 (es)
PT (2) PT2561876E (es)
RS (1) RS53419B (es)
SI (1) SI2561876T1 (es)
SM (1) SMT201400094B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
CA2827643C (en) 2011-02-18 2019-05-07 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
WO2017079700A1 (en) * 2015-11-04 2017-05-11 Kythera Biopharmaceuticals, Inc. Treatments of accumulated fat with deoxycholic acid and salts thereof
CN118005707A (zh) * 2024-01-18 2024-05-10 山东省食品药品检验研究院 一种脱氧胆酸钠晶型a及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
US6417179B1 (en) * 1998-10-13 2002-07-09 Craig G. Burkhart Ear wax solution
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
ES2372499T3 (es) 2004-05-19 2012-01-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Uso de un detergente para la eliminación no quirúrgica de grasa.
US7754230B2 (en) 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
EP1888101B1 (en) 2005-06-06 2012-03-21 Georgetown University Compositions and methods for lipo modeling
TW201011755A (en) 2008-09-10 2010-03-16 Skymedi Corp Flash memory system and its data recovery method

Also Published As

Publication number Publication date
RS53419B (sr) 2014-12-31
EP2561876B1 (en) 2014-04-16
HUE046047T2 (hu) 2020-01-28
DK3305298T3 (da) 2019-07-29
DK2561876T3 (da) 2014-07-21
PL3305298T3 (pl) 2020-02-28
EP2735310A1 (en) 2014-05-28
PT2561876E (pt) 2014-07-18
SMT201400094B (it) 2014-11-10
EP3305298B1 (en) 2019-05-01
ES2655465T3 (es) 2018-02-20
PT3305298T (pt) 2019-07-29
EP2735310B1 (en) 2017-10-11
ES2738500T3 (es) 2020-01-23
CY1115372T1 (el) 2017-01-04
PL2561876T3 (pl) 2014-09-30
HRP20140676T1 (hr) 2014-10-10
EP3305298A1 (en) 2018-04-11
EP3511007A1 (en) 2019-07-17
SI2561876T1 (sl) 2014-08-29
EP2561876A1 (en) 2013-02-27

Similar Documents

Publication Publication Date Title
ES2634490T3 (es) Derivados de ácido napht-2-ylacetico para tratar el sida
CR20140053A (es) Formulaciones de ácido desoxicólico y sales del mismo
ES2563323T3 (es) Procedimiento para la preparación de un sólido cristalino a partir de derivados de ácido glicin-N,N-diacético
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
ES2509117T3 (es) Composición farmacéutica oral que contiene dabigatran etexilato
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
MX352949B (es) Composicion farmaceutica.
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
AR088018A1 (es) Proceso e intermediarios para preparar lapatinib
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
AR081870A1 (es) Composicion farmaceutica que comprende un derivado de amida o sal farmaceuticamente aceptable del mismo
CL2011001225A1 (es) Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros.
CR9703A (es) Derivados de pirazolona
CU24330B1 (es) Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
ES2527639T3 (es) Composición de limpieza antimicrobiana con bajo contenido de alcohol
AR090592A1 (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil}amino)-1-hidroxietil]-8-hidroxiquinolin-2(1h)-ona
AR093126A1 (es) Formulaciones de liberacion modificada para oprozomib
MX2015012109A (es) Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso.
AR063027A1 (es) Derivados de sulfonamida
ES2660019T3 (es) Parche que contiene diclofenaco y tiocolchicósido
AR109168A1 (es) Sales de derivados de 2,6-dimetilpirimidona y sus usos
PE20130374A1 (es) Composicion farmaceutica que comprende ibuprofeno
UY34916A (es) "preparación sólida que contiene ácido[(3s)-6-){2´,6´-dimetil-4´-[3-(metilsulfonil)propoxi]bifenil-3-il}metoxi)-2,3-dihidro-1-benzofuran-3-il]acético"
MX366174B (es) Composicion de cuidado oral.